Health Canada classifies estrogen patches as a Tier 3 drug shortage

Health Canada’s Tier Assignment Committee added estrogen transdermal patches to the federal Tier 3 drug-shortage list on Oct. 28, 2026. Tier 3 is reserved for shortages with the greatest potential impact on Canada’s drug supply and health-care system. The notice identifies the affected drug class broadly; it does not name a manufacturer, drug identification number (DIN), strength, brand, province or expected duration. It therefore does not establish that every estrogen patch product is unavailable. Health Canada’s Tier 3 list is the primary source for the determination.

Illustrative only; the image does not depict a specific product or confirm a shortage.

Key takeaways

• The Tier 3 determination is dated Oct. 28 and applies to estrogen transdermal patches as a class.
• Health Canada says Tier 3 shortages have the greatest potential impact; the assignment itself is not a product-by-product inventory report.
• Some affected drugs may be eligible for exceptional importation, but importation is permitted only when the relevant product is listed through the separate federal process.
• Pharmacies should confirm the exact formulation and local supply before advising patients or changing therapy.

What the designation means

Health Canada says the Tier Assignment Committee considers medical necessity, the availability of alternative supplies, ingredients or therapies, the information gathered about a shortage, and possible mitigation steps. The committee includes federal and provincial representation and health-care and industry stakeholders. The designation elevates the potential system impact; it does not tell pharmacies which DINs to order or whether a specific patient’s prescription can be filled.

Tier 3 status can make a drug eligible for exceptional importation and sale to mitigate a critical shortage. However, Health Canada directs readers to a separate list of drugs authorized for exceptional importation. A class-level entry on the Tier 3 page is not, by itself, permission to import or dispense a foreign product. Pharmacists should check the current federal exceptional-importation list and applicable provincial requirements before acting.

What remains unclear

The public notice does not specify the affected patch strengths, brands, manufacturers, start or end dates, or whether the issue is a confirmed shortage or an anticipated risk. Nor does it provide patient-level recommendations for switching hormone therapy. Those details matter: transdermal products are not automatically interchangeable solely because they share an ingredient or route, and treatment changes should be based on the prescribed product, the patient’s needs and current professional guidance.

This designation is separate from the earlier British Columbia PharmaCare notice about adhesion problems with some menopausal hormone-therapy patches. That product-use issue is distinct from this federal shortage designation; the two notices should not be assumed to share a cause or affected products.

Practice guidance for pharmacists

• Check the current Drug Shortages Canada database and supplier notices for the specific DIN, strength and manufacturer before telling a patient that their product is unavailable.
• Review the prescription and confirm the patch’s strength, application schedule and indication before discussing an alternative; do not substitute a different estrogen product on the basis of the Tier 3 notice alone.
• If a change is clinically appropriate, consult the prescriber and follow provincial rules, the product monograph and the patient’s treatment plan.
• Do not import or dispense an exceptional-importation product unless the exact product is listed and the applicable federal and provincial conditions are met.
• Explain what is confirmed and what is still unknown, document supply-related decisions, and arrange follow-up so patients are not left without a plan.

What happens next

Health Canada’s shortage pages and the manufacturer-reported database are the places to monitor for product-level updates, duration estimates and any exceptional-importation authorization. Until those details are posted, the practical message is to verify local supply and avoid assuming that all estrogen patches—or all alternatives—are affected.